Navigation Links
Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
Date:1/4/2008

ck,

non-fatal stroke or cardiovascular death (p<0.001).

-- 52 percent reduction compared with clopidogrel in stent thrombosis

(p<0.0001).

-- 30 percent relative risk reduction compared to clopidogrel in a subset

of patients with diabetes (p<0.001) on the composite endpoint of non-

fatal heart attack, non-fatal stroke, or cardiovascular death.

Risk reductions in the primary composite endpoint with prasugrel compared to clopidogrel were seen as early as three days and continued to diverge for 15 months (the duration of the trial.)

Though the incidence of non-coronary artery bypass grafting(non-CABG) bleeding in TRITON was low in both the prasugrel and clopidogrel treatment groups, prasugrel-treated patients experienced significantly higher non-CABG major bleeding (2.2% vs. 1.7%, respectively) and higher rates of life- threatening bleeding (1.3% vs. 0.8%, respectively). Death from cardiovascular causes (2% vs. 2.2%, respectively) and all-cause death (2.8% vs. 2.9%, respectively) was comparable among prasugrel-treated patients and clopidogrel- treated patients. The overall results demonstrated that for every 1,000 patients treated with prasugrel as compared with clopidogrel, there were 22 fewer patients with heart attacks and five more non-CABG-related TIMI major bleeds.

"Given the overall results from TRITON, this submission is particularly meaningful considering that cardiovascular disease is the leading cause of death in the United States and worldwide, killing 16.7 million people each year," said John Alexander, M.D., M.P.H., global head of research and development, Daiichi Sankyo Company, Limited.

Acute heart attacks and unstable angina, called acute coronary syndrome, affect more than 840,000 Americans each year and 800,000 people in Europe.(i,ii) Utilizing current medical interventions and treatments, 300,000 people continue to experience recurrent heart attacks and 450,000 people die fro
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
2. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
3. Lilly Declares Fourth-Quarter Dividend
4. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
5. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
6. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Cephalon Submits Supplemental New Drug Application for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SC (PRWEB) October 22, 2014 ... of its cardiovascular pharmacogenetics menu, which enables healthcare ... outcomes. With PCLS’s evidence-based results, healthcare providers ... and optimize their therapy, while minimizing risks for ... the U.S., according to the FDA [1] more ...
(Date:10/22/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... its Oral Amphotericin B program.  The company recently ... work involving samples from HIV/AIDS patients exposed ... pre clinical studies and regulatory filings to move ... utilizing approximately $700,000 of funding and technological advice ...
(Date:10/22/2014)... DIEGO and HONG KONG ... innovative rare disease therapeutics enterprise, announced today that rare ... the company as vice president, research. Dr. McKew brings ... including key leadership positions at the National Institutes of ... its acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts ...
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... Conn. , April 28 Goodwin Biotechnology Inc., a full ... development services company, jointly announced today their collaborative agreement to create ... services. , , , ... collaboration will enhance and strengthen the clinical development services integrating cDNA ...
... 28 The global biotechnology industry was able to ... financial performance in 2009, with the world,s established biotech centers ... gap between the "haves" and "have nots" in the industry ... companies in accessing the capital needed for R&D. These and ...
... ... of its Global Food, Agribusiness and Biofuels practice, presents findings today from a new ... and Agricultural Infrastructure" at the Land Conference 2010 organized by The World Bank in ... ...
Cached Biology Technology:Goodwin Biotechnology Inc. and Hyprocell LLC Announce Collaboration 2Goodwin Biotechnology Inc. and Hyprocell LLC Announce Collaboration 3Biotech Industry Showing Resilience Despite Challenging Conditions 2Biotech Industry Showing Resilience Despite Challenging Conditions 3Biotech Industry Showing Resilience Despite Challenging Conditions 4Biotech Industry Showing Resilience Despite Challenging Conditions 5Biotech Industry Showing Resilience Despite Challenging Conditions 6Biotech Industry Showing Resilience Despite Challenging Conditions 7Private Sector Investment in Agriculture Emerging as a Significant Alternative Asset Class: New HighQuest Partners Study 2Private Sector Investment in Agriculture Emerging as a Significant Alternative Asset Class: New HighQuest Partners Study 3Private Sector Investment in Agriculture Emerging as a Significant Alternative Asset Class: New HighQuest Partners Study 4
(Date:10/25/2014)... A recent report, "Genetic Testing Market Outlook 2018", provides ... testing market. A comprehensive introduction of gene-based tests, their ... On account of our analysis of the past and ... forecast for genetic testing has been drawn, according to ... CAGR of around 9% during 2013-2018. Our report ...
(Date:10/22/2014)... (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended September 30, 2014. Revenue for the ... 40% compared to $4.3 million in the same quarter last ... $4.1 million compared to $1.0 million in the third quarter ... period was primarily due to: i) a $1.0 million increase ...
(Date:10/17/2014)... is critical and pertinent for practicing physicians and clinicians ... epidemic. The Journal, Disaster Medicine and Public Health ... and Public Health, to surround the public, medical professionals ... moment. , On October 17, the journal published ... primer was prepared by Dr. Eric Toner, internist and ...
Breaking Biology News(10 mins):Genetic Testing Market Outlook 2018 2Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7
... Groundbreaking research led by the U.S. Department of Energy ... time that the signatures of the genes alone in ... of the sampled environments. This study, published in the ... genome sequencing to accelerate advances in environmental sciences akin ...
... throughput microarray analyses result in many differentially expressed ... process of interest. In order to identify biological ... in which pairs of gene names and combinations ... , MEDLINE search strings for 15,621 known genes ...
... Joslin Diabetes Center have found genetic regions that, when defective, ... in a series of mis-steps that lead to type 1 ... journal Immunity, the researchers are now trying to hone in ... patients. , “The significance of this study is that we ...
Cached Biology News:Study reveals new technique for fingerprinting environmental samples 2Study reveals new technique for fingerprinting environmental samples 3Genetic defects give the immune system the green light to attack the pancreas 2Genetic defects give the immune system the green light to attack the pancreas 3
Determine relative degree of protein binding to phosphoinositides...
PA coated Agarose beads LPA Beads...
Mouse monoclonal antibody to RNase L...
Volume adapter mounts on top of the 96 well FiltrEX filter plate and allows larger volumes (1mL) to be applied to each well in a filter plate. Adapters are nonsterile....
Biology Products: